Pharmaceutical Commerce - March/April 2013 - (Page 1)

MARCH/APRIL 2013 Brand Marketing & Communications Information Technology Sales automation tools make strides in Pharma struggles to manage the complexity of its Patient Assistance Programs addressing industry needs While awaiting the effects of the Affordable Care Act on PAPs, industry and its service providers wrestle with conflicting priorities By Suzanne Shelley, Contributing Editor Not too long ago, the mission of Patient Assistance Programs (PAPs) operated by bioph armaceutical companie s was f air ly straightforward: give free or reduced-cost branded medications to those patients who could not afford them. While the drug-specific eligibility criteria typically vary from program to program, eligibility has typically been based on a relatively small set of factors—primarily the patient’s income relative to the federal poverty limit (FPL), number of family This assistance card from RxHope, a Triplefin members and a few others. company, can be used at 60,000 pharmacies “A decade ago, patients who had insurance were nationwide. Credit: RxHope generally able to afford their medications,” says Tracy Foster, president of Lash Group (Charlotte, NC), a unit of AmerisourceBergen Consulting Services. “Today, many factors impact medication affordability.” These include the stagnant economy, increasing drug costs, a growing market for expensive oral medications and extremely costly specialty, orphan or ultra-orphan drugs, the increased use of complex, multi-drug treatment regimens, an overall trend toward higher out-of-pocket expenses (such as higher insurance premiums, deductibles and coinsurance requirements) as employers shift more of their rising healthcare costs to their employees. During each of the past four years, Lash Group has surveyed roughly 85 PAP administrators to track trends in the market. Roughly half of the PAPs surveyed have expanded the financial criteria of their programs, to help those whose financial needs have grown during these challenging economic times. Similarly, in 2012, 31% of PAP administrators reported an expansion of other eligibility criteria for free product assistance, so that they now include not only patients who have no insurance, but also those who may be “functionally uninsured” because their insurance does not cover medications, or creates high deductibles or cost shares compared to disposable income, says Foster. “Our estimate is that nationally, the pharma industry spends $5 billion on PAPs,” says Edward Petrella, president of CareNet Foundation, a PAP-service firm in Cary, NC. “To that can be added some portion—we believe that it’s around 65–70%—of the $14 billion the industry spends annually on physician sampling.” Thus, the entire PAP support, from pharma, is almost $15 billion. Meanwhile, as healthcare reform rolls forward, there is still considerable uncertainty about what the impact of the Affordable Care Act (ACA or “Obamacare”) will be on the entire healthcare arena, and on PAPs and related copay-relief initiatives specifically. ACA-driven healthcare reforms will—by definition—reduce the number of individuals who are technically “uninsured” (by forcing nearly 30 million uninsured Americans to join expanded Medicaid programs or state-level health insurance continued on page 20 The near-takeover of detailing with the Apple iPad has created a springboard for new applications By Nicholas Basta What a difference 30 seconds make! That’s generally regarded as the difference in loading time between an Apple iPad and most types of laptop computers. And because pharma sales reps average between one and two minutes of face time when visiting physicians, those 30 seconds could become half of the time available for the interaction. That’s only one of the many reasons that sales forces throughout the worldwide life sciences industry have jumped onto the iPad platform; Apple’s interactive tablet is, of course, one of the most successful consumer electronics products in years, lauded for its convenience, ease of use and pleasantly viewed graphics. The iPad, in turn, has generated an upheaval in pharma sales force automation (SFA)—and that upheaval is having a ripple effect on overall pharma sales and marketing activities. continued on page 28 Manufacturing & Packaging Transdermal drug delivery looks for new frontiers Microneedles and ‘active’ patches extend the reach of transdermal applications By Peggy Wright, Contributing Editor The skin, the largest organ, effectively prevents passage of many foreign substances into the body. Passive transdermal products, such as patches and gels, creams, and sprays are able to pass some drugs through the skin at therapeutic rates to deliver drugs systemically. Drugs that are lipophilic, with low molecular weights and low dosages, can pass through the skin most easily. Not all small-molecule drugs, however, can do so; e.g., charged molecules. To enable delivery, products often use various passive technologies, including: • Particulate systems, such as liposomes, transfersomes (synthetic vesicles), microemulsions, or solid lipid nanoparticles • Chemical penetration enhancers, such as glycols and terpenes The skin provides an effective barrier as well to large-molecule drugs, such as continued on page 30 PONTIAC, IL PERMIT 268 PAID March | April 2013 Visit our website at www.PharmaceuticalCommerce.com 1 PRSRT STD US POSTAGE http://www.PharmaceuticalCommerce.com http://www.PharmaceuticalCommerce.com

Table of Contents for the Digital Edition of Pharmaceutical Commerce - March/April 2013

Pharmaceutical Commerce - March/April 2013
Editorial
Contents
Op-Ed
Top News
Business/Finance
Brand Marketing & Communications
Supply Chain/Logistics
Information Technology
Manufacturing & Packaging
Legal & Regulatory
Meetings and Editorial Index

Pharmaceutical Commerce - March/April 2013

https://www.nxtbook.com/nxtbooks/pharmcomm/202006
https://www.nxtbook.com/nxtbooks/pharmcomm/202003
https://www.nxtbook.com/nxtbooks/pharmcomm/201911
https://www.nxtbook.com/nxtbooks/pharmcomm/201909
https://www.nxtbook.com/nxtbooks/pharmcomm/201906
https://www.nxtbook.com/nxtbooks/pharmcomm/201903
https://www.nxtbook.com/nxtbooks/pharmcomm/201811
https://www.nxtbook.com/nxtbooks/pharmcomm/201809
https://www.nxtbook.com/nxtbooks/pharmcomm/201806
https://www.nxtbook.com/nxtbooks/pharmcomm/20180304
https://www.nxtbook.com/nxtbooks/pharmcomm/20171112
https://www.nxtbook.com/nxtbooks/pharmcomm/20170910
https://www.nxtbook.com/nxtbooks/pharmcomm/20170708
https://www.nxtbook.com/nxtbooks/pharmcomm/20170506
https://www.nxtbook.com/nxtbooks/pharmcomm/20170304
https://www.nxtbook.com/nxtbooks/pharmcomm/20170102
https://www.nxtbook.com/nxtbooks/pharmcomm/20161112
https://www.nxtbook.com/nxtbooks/pharmcomm/20160910
https://www.nxtbook.com/nxtbooks/pharmcomm/20160708
https://www.nxtbook.com/nxtbooks/pharmcomm/20160506
https://www.nxtbook.com/nxtbooks/pharmcomm/20160304
https://www.nxtbook.com/nxtbooks/pharmcomm/20160102
https://www.nxtbook.com/nxtbooks/pharmcomm/20151112
https://www.nxtbook.com/nxtbooks/pharmcomm/20150910
https://www.nxtbook.com/nxtbooks/pharmcomm/20150708
https://www.nxtbook.com/nxtbooks/pharmcomm/20150506
https://www.nxtbook.com/nxtbooks/pharmcomm/20150304
https://www.nxtbook.com/nxtbooks/pharmcomm/20150102
https://www.nxtbook.com/nxtbooks/pharmcomm/20141112
https://www.nxtbook.com/nxtbooks/pharmcomm/coldchaindirectory2014
https://www.nxtbook.com/nxtbooks/pharmcomm/20140910
https://www.nxtbook.com/nxtbooks/pharmcomm/20140708
https://www.nxtbook.com/nxtbooks/pharmcomm/20140506
https://www.nxtbook.com/nxtbooks/pharmcomm/20140304
https://www.nxtbook.com/nxtbooks/pharmcomm/20140102
https://www.nxtbook.com/nxtbooks/pharmcomm/dataservicedirectory
https://www.nxtbook.com/nxtbooks/pharmcomm/20131112
https://www.nxtbook.com/nxtbooks/pharmcomm/20130910_hubreport
https://www.nxtbook.com/nxtbooks/pharmcomm/20130910
https://www.nxtbook.com/nxtbooks/pharmcomm/20130708
https://www.nxtbook.com/nxtbooks/pharmcomm/20130506
https://www.nxtbook.com/nxtbooks/pharmcomm/coldchain2013
https://www.nxtbook.com/nxtbooks/pharmcomm/20130304
https://www.nxtbook.com/nxtbooks/pharmcomm/20130102
https://www.nxtbook.com/nxtbooks/pharmcomm/20121112
https://www.nxtbook.com/nxtbooks/pharmcomm/20120910
https://www.nxtbook.com/nxtbooks/pharmcomm/20120708
https://www.nxtbook.com/nxtbooks/pharmcomm/20120506
https://www.nxtbook.com/nxtbooks/pharmcomm/20120506_coldchain
https://www.nxtbook.com/nxtbooks/pharmcomm/20120304
https://www.nxtbook.com/nxtbooks/pharmcomm/20120102
https://www.nxtbook.com/nxtbooks/pharmcomm/20111112
https://www.nxtbook.com/nxtbooks/pharmcomm/20110910
https://www.nxtbook.com/nxtbooks/pharmcomm/20110708
https://www.nxtbook.com/nxtbooks/pharmcomm/20110506
https://www.nxtbook.com/nxtbooks/pharmcomm/20110304
https://www.nxtbook.com/nxtbooks/pharmcomm/20110102
https://www.nxtbook.com/nxtbooks/pharmcomm/20101112
https://www.nxtbook.com/nxtbooks/pharmcomm/20100910
https://www.nxtbook.com/nxtbooks/pharmcomm/20100708
https://www.nxtbook.com/nxtbooks/pharmcomm/20100506
https://www.nxtbook.com/nxtbooks/pharmcomm/201004
https://www.nxtbook.com/nxtbooks/pharmcomm/201003
https://www.nxtbook.com/nxtbooks/pharmcomm/20100102
https://www.nxtbook.com/nxtbooks/pharmcomm/20091112
https://www.nxtbookmedia.com